Literature DB >> 10369069

Increased AP-1 activity in drug resistant human breast cancer MCF-7 cells.

P J Daschner1, H P Ciolino, C A Plouzek, G C Yeh.   

Abstract

The expression, DNA binding, and transactivating activity of activator protein 1 (AP-1) was examined in a series of multidrug resistant (MDR) MCF-7 human breast cancer cells that have increasing levels of MDR1 gene expression. We observed an increase in the amount of both c-jun and c-fos mRNA in cells with 12-, 65-, or 200-fold higher resistance to adriamycin when compared to drug-sensitive MCF-7 wild type (WT) cells. Electrophoretic mobility shift assays (EMSA) demonstrated an increase in the DNA binding activity of an AP-1 complex in nuclear extracts from MDR MCF-7 cells when compared to extracts from WT cells. We observed a proportional increase in luciferase expression from a reporter vector containing consensus AP-1 binding sites in transiently transfected MDR cells when compared to WT cells, indicating that AP-1 mediated gene expression is increased in drug-resistant MCF-7 cells. Since the MDR1 promoter contains a putative AP-1 binding site, we used EMSA to examine AP-1 binding activity to an oligonucleotide probe that contained the relevant MDR1 promoter sequences (-123 to -108). Nuclear extracts from resistant MCF-7 cells displayed an increased level of DNA binding of Jun/Jun dimers to the probe, indicating that AP-1 was capable of binding to this promoter site. A luciferase reporter construct containing triplicate copies of the MDR1 promoter sequence was expressed at higher levels in transiently transfected MDR cells when compared to expression in WT cells. Co-transfection of WT cells with a c-jun expression vector and either of the AP-1 luciferase constructs demonstrated that c-jun could activate gene expression from both the consensus and the MDR1 AP-1 sites in a dose dependent manner. In addition, RT-PCR and western blot analysis showed that levels of MDR1 mRNA and Pgp were increased in c-jun transfected WT cells. Taken together, these data indicate that increased AP-1 activity may be an important mediator of MDR by regulating the expression of MDR1.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10369069     DOI: 10.1023/a:1006138803392

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  27 in total

1.  Reconstruction of transcriptional regulatory networks by stability-based network component analysis.

Authors:  Xi Chen; Jianhua Xuan; Chen Wang; Ayesha N Shajahan; Rebecca B Riggins; Robert Clarke
Journal:  IEEE/ACM Trans Comput Biol Bioinform       Date:  2013 Nov-Dec       Impact factor: 3.710

Review 2.  Recapitulation of complex transport and action of drugs at the tumor microenvironment using tumor-microenvironment-on-chip.

Authors:  Bumsoo Han; Chunjing Qu; Kinam Park; Stephen F Konieczny; Murray Korc
Journal:  Cancer Lett       Date:  2015-12-10       Impact factor: 8.679

3.  Preventing chemoresistance of human breast cancer cell line, MCF-7 with celecoxib.

Authors:  Chen Chen; Hui Ling Shen; Jing Yang; Qiao Yun Chen; Wen Lin Xu
Journal:  J Cancer Res Clin Oncol       Date:  2010-03-14       Impact factor: 4.553

Review 4.  The normal and malignant mammary gland: a fresh look with ER beta onboard.

Authors:  M Warner; S Saji; J A Gustafsson
Journal:  J Mammary Gland Biol Neoplasia       Date:  2000-07       Impact factor: 2.673

5.  Differential chemosensitization of P-glycoprotein overexpressing K562/Adr cells by withaferin A and Siamois polyphenols.

Authors:  Wipob Suttana; Samlee Mankhetkorn; Wilart Poompimon; Ajay Palagani; Sergey Zhokhov; Sarah Gerlo; Guy Haegeman; Wim Vanden Berghe
Journal:  Mol Cancer       Date:  2010-05-03       Impact factor: 27.401

6.  Multiple kinase cascades mediate prolactin signals to activating protein-1 in breast cancer cells.

Authors:  Jennifer H Gutzman; Debra E Rugowski; Matthew D Schroeder; Jyoti J Watters; Linda A Schuler
Journal:  Mol Endocrinol       Date:  2004-08-19

7.  Methylation-controlled J protein promotes c-Jun degradation to prevent ABCB1 transporter expression.

Authors:  Ketki M Hatle; Wendy Neveu; Oliver Dienz; Stacia Rymarchyk; Ramiro Barrantes; Sarah Hale; Nicholas Farley; Karen M Lounsbury; Jeffrey P Bond; Douglas Taatjes; Mercedes Rincón
Journal:  Mol Cell Biol       Date:  2007-02-05       Impact factor: 4.272

8.  Differential regulation of c-Jun protein plays an instrumental role in chemoresistance of cancer cells.

Authors:  Yan Xia; Weiwei Yang; Wen Bu; Haitao Ji; Xueqiang Zhao; Yanhua Zheng; Xin Lin; Yi Li; Zhimin Lu
Journal:  J Biol Chem       Date:  2013-05-15       Impact factor: 5.157

9.  Epigenetic Regulation of Multidrug Resistance Protein 1 and Breast Cancer Resistance Protein Transporters by Histone Deacetylase Inhibition.

Authors:  Dahea You; Jason R Richardson; Lauren M Aleksunes
Journal:  Drug Metab Dispos       Date:  2020-03-19       Impact factor: 3.922

10.  SH3GL1 inhibition reverses multidrug resistance in colorectal cancer cells by downregulation of MDR1/P-glycoprotein via EGFR/ERK/AP-1 pathway.

Authors:  Haitao Guan; Ping Zhao; Zhijun Dai; Xiaoxu Liu; Xijing Wang
Journal:  Tumour Biol       Date:  2016-05-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.